Celldex Therapeutics (FRA:TCE2) Cyclically Adjusted Book per Share: €12.12 (As of Mar. 2026)


FRA:TCE2 Celldex Therapeutics Inc FRA:TCE2
58 GF Score
Price €33.01
GF Value €6.14
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Cyclically Adjusted Book per Share?

Celldex Therapeutics FRA:TCE2 +3.64% 58 Cyclically Adjusted Book per Share is €12.12 as of Mar. 2026. GuruFocus rates FRA:TCE2 with a GF Score™ of 58/100 and a GF Value™ of €6.14 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Celldex Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €5.928. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €12.12 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Celldex Therapeutics's average Cyclically Adjusted Book Growth Rate was -24.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -17.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -11.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Celldex Therapeutics was 6.30% per year. The lowest was -18.30% per year. And the median was -8.80% per year.

As of today (2026-07-05), Celldex Therapeutics's current stock price is €33.01. Celldex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €12.12. Celldex Therapeutics's Cyclically Adjusted PB Ratio of today is 2.72.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Celldex Therapeutics was 2.64. The lowest was 0.05. And the median was 1.14.


Celldex Therapeutics  (FRA:TCE2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Celldex Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=33.01/12.12
=2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Celldex Therapeutics was 2.64. The lowest was 0.05. And the median was 1.14.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Celldex Therapeutics Cyclically Adjusted Book per Share Related Terms


Celldex Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Cyclically Adjusted Book per Share Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.45 26.50 22.71 20.42 12.89

Celldex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.88 15.97 14.69 12.89 12.12

FRA:TCE2 vs TARS, KLRA, IRON: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:TCE2
58GF Score
Celldex Therapeutics Inc FRA:TCE2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celldex Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5.928/330.2130*330.2130
=5.928

Current CPI (Mar. 2026) = 330.2130.

Celldex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 31.526 241.018 43.193
201609 28.656 241.428 39.194
201612 31.321 241.432 42.839
201703 27.993 243.801 37.915
201706 24.252 244.955 32.693
201709 20.878 246.819 27.932
201712 21.628 246.524 28.970
201803 11.377 249.554 15.054
201806 10.496 251.989 13.754
201809 9.771 252.439 12.781
201812 9.119 251.233 11.986
201903 7.764 254.202 10.086
201906 6.548 256.143 8.442
201909 5.788 256.759 7.444
201912 4.986 256.974 6.407
202003 4.272 258.115 5.465
202006 5.416 257.797 6.937
202009 4.935 260.280 6.261
202012 4.345 260.474 5.508
202103 4.117 264.877 5.133
202106 3.819 271.696 4.642
202109 7.955 274.310 9.576
202112 7.944 278.802 9.409
202203 7.731 287.504 8.879
202206 7.385 296.311 8.230
202209 7.408 296.808 8.242
202212 6.524 296.797 7.259
202303 5.985 301.836 6.548
202306 5.421 305.109 5.867
202309 4.891 307.789 5.247
202312 7.042 306.746 7.581
202403 11.706 312.332 12.376
202406 11.404 314.175 11.986
202409 10.673 315.301 11.178
202412 10.748 315.605 11.245
202503 9.795 319.799 10.114
202506 8.559 322.561 8.762
202509 7.672 324.800 7.800
202512 6.765 324.054 6.894
202603 5.928 330.213 5.928

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €12.12 mean?
Celldex Therapeutics (FRA:TCE2) has a Cyclically Adjusted Book per Share of €12.12 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Cyclically Adjusted Book per Share too high?
Celldex Therapeutics' current Cyclically Adjusted Book per Share is €12.12. Overall, Celldex Therapeutics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Cyclically Adjusted Book per Share compare to TARS and KLRA?
Celldex Therapeutics' Cyclically Adjusted Book per Share of €12.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Cyclically Adjusted Book per Share is €12.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (FRA:TCE2) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.14, compared to a current price of €33.01 — trading 437.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is €12.12. Celldex Therapeutics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Celldex Therapeutics (FRA:TCE2), the current Cyclically Adjusted Book per Share is €12.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (FRA:TCE2) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of €33.01 is trading 437.6% above its estimated GF Value™ of €6.14. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:TCE2:

  • Cyclically Adjusted Book per Share: €12.12
  • GF Value™: €6.14 vs. price of €33.01 (437.6% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the FRA:TCE2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celldex Therapeutics Business Description

Other Exchanges CLDX:USA
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
58GF Score

Get the complete analysis for FRA:TCE2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.01
Price
€6.14
GF Value